Network meta-analysis compares therapies for liver metastatic uveal melanoma
Liver-directed therapy combined with ICIs leads for metastatic uveal melanoma survival
This systematic review and network meta-analysis synthesized evidence on therapeutic modalities for patients with liver metastatic uveal mel…
A network meta-analysis of 2,585 patients found liver-directed therapy combined with immune checkpoint inhibitors offered the best survival …
Combined tebentafusp and SBRT showed disease control in a patient with metastatic uveal melanoma
One Woman’s Rare Eye Cancer Spread. Then a New Combo Stopped It Cold
This case report describes a 39-year-old woman with localized uveal melanoma who developed liver and hilar adenopathy metastases.
This story shows how combining a new immune drug with targeted radiation may help the body fight cancer longer, even after it has spread.
Immunoembolization shows lower disease control than FOCUS trial in liver-dominant metastatic uveal melanoma
Eye Cancer in Liver: New Therapy Extends Life Even When Tumors Grow
This single-center retrospective analysis evaluated immunoembolization (IE) in 43 patients with liver-dominant metastatic uveal melanoma.
A new liver treatment for eye cancer patients may help them live longer, even if it does not shrink tumors as much as expected.
Phase II trial compares IMCgp100 vs investigator choice in advanced uveal melanoma
Can a new drug help people with a rare eye cancer live longer?
This Phase II study evaluated IMCgp100 versus investigator's choice (dacarbazine, ipilimumab, or pembrolizumab) in HLA-A*0201 positive adult…
A new drug for advanced eye cancer is being compared to standard treatments to see if it helps patients with a specific genetic marker live …
Research across Melanoma
Related studies from across the Melanoma family.
Narrowband UVB remains first-line phototherapy for vitiligo, with JAK inhibitors emerging as adjuncts
New light therapies and skin grafts offer hope for vitiligo patients
This narrative review synthesizes current evidence on phototherapy for vitiligo, highlighting narrowband UVB as the mainstay. Excimer lasers…
A review of treatments for vitiligo highlights options like narrowband ultraviolet B light, excimer therapy, and cellular grafting that may …
Meta-analysis finds modest melanoma risk increase among infertile women using fertility treatments
Fertility Drugs Linked to Slight Rise in Melanoma Risk
This systematic review and meta-analysis evaluated melanoma incidence in infertile women exposed to fertility treatments compared to untreat…
A large review finds fertility drugs may raise melanoma risk slightly, but the increase is small and more research is needed.
TIL therapy and engineered viral vector immunotherapies show pooled ORR of 37.8% in advanced melanoma
First new analysis in years shows TIL therapy response rates for advanced melanoma
This Bayesian meta-analysis synthesizes data from 13 eligible studies on TIL therapy and engineered viral vector immunotherapies for advance…
A Bayesian meta-analysis of 13 studies finds TIL therapy yields a 49% response rate in advanced melanoma, with moderate certainty for respon…
Systematic Review: Intercellular Mitochondrial Transfer in Melanoma Progression and Resistance
Mitochondrial Transfer Fuels Melanoma Resistance and Spread
This systematic review examines the role of intercellular mitochondrial transfer in melanoma. The authors find that this process contributes…
A systematic review reveals that intercellular mitochondrial transfer helps melanoma resist therapies and spread, but may also suppress tumo…
Meta-analysis finds germline LTS and somatic TERT variants are mutually exclusive in thyroid cancer and melanoma
Two different cancer drivers do not appear together in these tumors
This meta-analysis of retrospective observational cohorts examined germline long-telomere syndrome variants and somatic TERT promoter altera…
A large review of nearly 2,000 adults with thyroid cancer or melanoma found that two specific genetic changes never occur in the same tumor.
Systematic review and meta-analysis of AI for melanoma risk assessment in pigmented skin lesions
AI plus doctors finds every skin cancer case in real-world settings
This systematic review and meta-analysis synthesized evidence from 17 diagnostic arms on AI, dermoscopy, and AI-assisted clinicians for mali…
When doctors used AI alongside standard skin checks, they caught every cancer case without missing any, showing a powerful new way to help p…
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
Systematic review and meta-analysis on alopecia areata and skin cancer risk
Alopecia areata patients may have lower risk of certain skin cancers based on new review data
This systematic review and meta-analysis synthesized eight studies on skin cancer risk in patients with alopecia areata. The analysis found …
This review found that people with hair loss might have a lower chance of getting melanoma. Other skin cancers showed a similar trend but th…
Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
Cancer Patients Live Longer When Immunotherapy Starts Early in Day
This systematic review and meta-analysis evaluated 6129 patients with advanced solid tumors receiving immune checkpoint inhibitors. Earlier …
• Morning immunotherapy shots link to longer survival for advanced cancers • Helps patients fighting lung stomach kidney and other tough can…
Meta-analysis of pucotenlimab shows improved outcomes across multiple solid tumors
New analysis shows pucotenlimab improves outcomes for several solid tumor types
This meta-analysis evaluated pucotenlimab (HX008) in patients with gastric, gastroesophageal junction, triple-negative breast cancer, melano…
A new analysis of pucotenlimab shows significantly improved outcomes versus control for patients with gastric cancer, triple-negative breast…
Narrative review discusses MicroRNAs in melanoma without reported outcomes or safety data
A review explores how MicroRNAs might relate to Melanoma
This narrative review examines the role of MicroRNAs in melanoma.
This narrative review discusses MicroRNAs in the context of Melanoma, offering a broad overview of current scientific understanding.
Methodological study evaluates synthetic image framework for melanoma classification accuracy in preprint report
New image method boosts tumor detection accuracy in melanoma datasets
This preprint describes a methodological study evaluating a hybrid framework using synthetic medical images to train convolutional neural ne…
A new way to train computer models improved how well they spot melanoma cells. This approach uses synthetic images to help computers learn b…
Questions about Uveal Melanoma
Did a patient with uveal melanoma benefit from combined tebentafusp and SBRT?
Yes, a case report describes a patient with metastatic uveal melanoma who achieved durable disease control after adding SBRT to tebentafusp, with a partial response and 35 months of maintained control.
Full answer →What treatments are available for liver metastatic uveal melanoma patients?
Liver-directed therapy combined with immune checkpoint inhibitors appears most effective; tebentafusp is approved for HLA-A*02:01+ patients; other options include immunoembolization, SBRT, and clinical trials.
Full answer →How does immunoembolization compare to the FOCUS trial for uveal melanoma?
Immunoembolization shows lower disease control rates than the FOCUS trial for liver-dominant metastatic uveal melanoma, though tebentafusp combined with radiotherapy may offer durable control in specific cases.
Full answer →Can tebentafusp and SBRT control disease in uveal melanoma?
Yes, a case report shows tebentafusp plus SBRT controlled metastatic uveal melanoma for over 35 months, but more research is needed to confirm this approach.
Full answer →